| 摘要 |
PROBLEM TO BE SOLVED: To provide a prophylactic or therapeutic agent for anemia which has an adverse side effect produced in interferon/ribavirin combination therapy. SOLUTION: An acidosis-ameliorating agent such as a preparation containing potassium citrate and sodium citrate (Uralyt-U, Uralyt Tablets (registered trade names)) is used as the prophylactic or therapeutic agent for anemia which has an adverse side effect produced in the interferon/ribavirin combination therapy. The interferon may include interferonα-2a, interferonα-2b, pegylated interferonα-2a, pegylated interferonα-2b, consensus interferon or purified interferonα. COPYRIGHT: (C)2011,JPO&INPIT
|
